Key result
Dabigatran maintains low stroke incidence at ~0.7 per 100 person-years in new-onset NVAF.
Why the study?
The safety and efficacy of dabigatran in patients with newly diagnosed nonvalvular atrial fibrillation at risk of stroke needed to be established in a multinational setting.
Observational (n=15,308)
Yes
NOACs have been highly adopted in clinical practice for nonvalvular AF, surpassing VKAs, though a large proportion of patients remain undertreated globally.
No takes yet. Share an insight, caveat, or question.
Baseline characteristics in GLORIA-AF Phase II reflect early NOAC adoption; leaves open long-term safety questions in new AF.
Dubner et al. (2020) conducted an observational in Non-valvular atrial fibrillation (n=15,308). Dabigatran was evaluated on Incidence of stroke (per 100 person-years) (95% CI 0.48-0.87). In patients with newly diagnosed non-valvular atrial fibrillation, dabigatran treatment demonstrated sustained safety and effectiveness over 2 years, with a stroke incidence of 0.65 per 100 person-years.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: